← Eichor
Condition: Egfr Activating Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Egfr Activating Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2 · 1 location(s) · TYK Medicines, Inc · NCT05948813CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
NA · 1 location(s) · British Columbia Cancer Agency · NCT05257967Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NA · 1 location(s) · Guangzhou University of Traditional Chinese Medicine · NCT07348965EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07637448Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant
NA · 36 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06053099A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brai
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06741085Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastas
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05768490A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip
Phase 3 · 285 location(s) · Bayer · NCT06452277Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3 · 2 location(s) · TYK Medicines, Inc · NCT05382728A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Phase 2 · 5 location(s) · National Cancer Center, Korea · NCT06156527A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Phase 1/Phase 2 · 42 location(s) · BlossomHill Therapeutics · NCT06706076A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Parti
Phase 2 · 54 location(s) · Bayer · NCT06760819
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.